Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study
The Oncologist · 05.11.2026 · 31 (12)
DOI: 10.1093/oncolo/oyag419 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, online erschienen am 20.10.2026. Verfasst von Sari Voutilainen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki FI-00029, Finland. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adjuvant cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have improved outcomes in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer (eBC) in the NATALEE and monarchE trials. However, real‑world evidence on the proportion of candidates for adjuvant CDK4/6 inhibitors and their outcomes within these trial-defined populations remains limited. Materials and Methods We conducted a retrospective, population‑based cohort study including all patients diagnosed with HR+/HER2– eBC in the Hospital District of Helsinki and Uusimaa, Finland, between January 2014 and June 2023. Patients were classified according to NATALEE and/or monarchE eligibility criteria. Outcomes assessed were invasive disease‑free survival (iDFS), distant disease‑free survival (DDFS), and overall survival (OS).
Results
Among 8911 patients with HR+/HER2- eBC and a median follow-up of 5.2 years, 40.4% met the NATALEE eligibility criteria and 15.0% met the monarchE criteria. Eligible patients were younger and had higher‑grade tumors and greater proliferation rate than non-eligible patients. Five‑year outcomes were consistently worse in eligible than ineligible patients (NATALEE: iDFS 82.5% vs 89.6%, DDFS 88.3% vs 94.5%, OS 90.9% vs 95.6%; monarchE: iDFS 76.8% vs 88.4%, DDFS 82.3% vs 93.8%, OS 86.8% vs 94.9%). Metastatic progression occurred 3‑ to 6‑fold more often in eligible patients. In multivariable models, both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality.
Conclusion
Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms. Trial‑defined eligibility criteria reliably identify patients with substantially poorer prognosis, supporting risk‑adapted adjuvant strategies and the integration of CDK4/6 inhibitors into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki FI-00029, Finland.
- Medaffcon Oy, Espoo, 02150, Finland.
- Novartis Finland Oy, Espoo, 02100, Finland.
- Novartis Sverige AB, Stockholm, 16440, Sweden.
ORCID-Profile: Sari Voutilainen, Samuli Tuominen, Liisa Ukkola-Vuoti, Maija Wolf, Peeter Karihtala
Zitieren
APA
Voutilainen, S., Tuominen, S., Ukkola-Vuoti, L., Hernesniemi, S., Engström-Risku, M., Paulsson, B., Wolf, M., & Karihtala, P. (2026). Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study. The Oncologist, 31(12). https://doi.org/10.1093/oncolo/oyag419
Vancouver
Voutilainen S, Tuominen S, Ukkola-Vuoti L, Hernesniemi S, Engström-Risku M, Paulsson B, et al. Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study. The Oncologist. 2026;31(12). doi:10.1093/oncolo/oyag419
BibTeX
@article{Voutilainen2026,
author = {Voutilainen, Sari and Tuominen, Samuli and Ukkola-Vuoti, Liisa and Hernesniemi, Sari and Engström-Risku, Mia and Paulsson, Björn and Wolf, Maija and Karihtala, Peeter},
title = {Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {12},
doi = {10.1093/oncolo/oyag419}
}
EUVIMED